Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of lung cancer involve non-small-cell lung cancer (NSCLC), in which therapy with immune checkpoint inhibitors (ICIs) can improve prognosis, yet up to 75% of patients fail to respond to it. Researchers at the Chinese Academy of Medical Sciences & Peking Union Medical College have identified potential metabolic markers that may help predict which patients are more likely to respond to ICI therapy.
Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA-approved T-VEC, have shown safety and some clinical benefit, their limited effectiveness as standalone treatments underscores the need for combination therapies.
Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions of the c-Myc promoter can form G-quadruplex structures, which can be targeted using small molecules containing a styrylquinolinium core, which then downregulate oncogenic c-Myc. The challenge, however, is specificity.
Scientists at Beijing Wehand-Bio Pharmaceutical Co. Ltd. and Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have synthesized phthalazinone compounds with neuroprotective effects reported to be useful for the treatment of hemorrhagic and ischemic stroke.
Scientists at Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have identified compounds reported to be useful for the treatment of cancer.
Understanding the mechanisms that drive the transition from an inflammatory to a proliferative phase during wound healing can aid in developing novel strategies for enhanced tissue repair. Keratinocytes, by undergoing reprogrammed gene expression, play crucial roles in both the inflammatory and proliferative phases of wound healing.
Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).
Researchers from Chinese Academy of Medical Sciences & Peking Union Medical College presented preclinical data for the new pan-peroxisome proliferator-activated receptor (PPAR) agonist, E-17241, being developed for the treatment of type 2 diabetes (T2D).
Investigators from the Chinese Academy of Medical Sciences & Peking Union Medical College presented data from a study that investigated the regulatory mechanisms of intestinal epithelial cell (IEC) death and intestinal inflammation.
